New York, NY, June 23, 2016 – Centinel Spine, Inc., (Centinel Spine), the pioneer of the No- Profile, Integrated Interbody™ fusion device market, is granted clearance for STALIF L™ No- Profile, Lateral Lumbar Integrated Interbody system by the Australian Therapeutic Goods Administration.
“This clearance expands our International No-Profile, Integrated Interbody market,” said John J. Viscogliosi, Chairman & CEO, Centinel Spine. “STALIF has enjoyed a long successful history in Australia and now STALIF L exemplifies our continued commitment to being the gold standard in Integrated Interbody devices. We are excited to bring the STALIF advantage to minimally-invasive spinal fusion surgery in Australia,” Mr. Viscogliosi continued.
STALIF L continues the thirty-year STALIF® heritage of innovation as STALIF L is the only lateral device to offer the benefits of no-profile, compressive lag fixation with proprietary anti-backout technology and 12-degrees of lordosis.
In addition to the above-mentioned STALIF benefits, STALIF L also offers a large chamber for bone graft to support fusion, optimized fixation with easily placed self-drilling, self-tapping screws and a variety of cage sizes to match patient anatomy.
Sam Scott-Young, Managing Director, Orthotech Orthopaedics Holdings, Ltd, Pty, exclaimed, “Orthotech is proud to represent Centinel Spine in Australia. We are excited to receive the STALIF L clearance enabling us to provide this innovative technology to our surgeon customers and their spine surgery patients. ”
Mr. Scott-Young continued, “The entire STALIF product portfolio, including the new STALIF L, and the Ti-ACTIVE™ technology, a texturized, titanium coating, allows our surgeon customers to offer their patients the most up-to-date spinal technologies with a heritage of more than 25 years of proven clinical success as a treatment for degenerative spinal pathologies.”
Centinel Spine also develops, manufactures, markets and sells the complete STALIF product family, which includes STALIF C®, STALIF C-Ti™, MIDLINE II™ and MIDLINE II-Ti™. STALIF C-Ti and MIDLINE II-Ti merge the proven clinical success of STALIF Integrated Interbody technology with Ti-ACTIVE, a texturized titanium coating developed with over 15 years of science and engineering experience. Recently, Centinel Spine received FDA clearance for ALTOS™ PCT, a posterior cervical stabilization system specifically designed for use in either the cervical lateral masses or cervical-thoracic pedicles.
For more information on STALIF L, please visit lateral.centinelspine.com.
About Centinel Spine, Inc.
Centinel Spine, Inc. is a privately-held spinal device company leading the development and commercialization of the No- Profile, Integrated Interbody fusion technologies. For more information on Centinel Spine products and technologies, please visit the Company’s web site at www.centinelspine.com.
The company began operations in August 2008, through the merger-acquisition of two pioneering medical device companies: Raymedica LLC and Surgicraft LTD. Today, Centinel Spine still embraces the pioneering culture developed at both originating companies and continues its corporate mission of becoming the leading anterior column support spine franchise, providing elegantly simple implants and instruments that are tissue-sparing and generate superior clinical outcomes.
Centinel Spine derived its name from the “Sentinel Sign” – the radiographic confirmation of a successful fusion anterior to the interbody device.
This information in this press release is intended for audiences in Australia. For more information, please contact:
Centinel Spine, Inc.
900 Airport Road, Suite 3B
West Chester, PA 19380